genitourinary disorders
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Treatment of ADPKD
Control of complications (eg, hypertension, infection, renal failure) Supportive measures Vasopressinantagonism or suppression Strict Treatment is essential. Typically an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker is used. In addition to controlling blood pressure, these medications help block angiotensin and aldosterone, growth factors that contribute to renal scarring and loss of renal function. Hemodialysis , Supportive measures include increased fluid intake (particularly water) to suppressvasopressinrelease, even if only partially, in patients who are able to safely excrete the load. receptor 2 antagonist, is a medication that may benefit patients with ADPKD ( Treatment references ). may slow the progression of structural kidney disease ( Treatment references ). 1.Torres VE, Chapman AB, Devuyst O:Tolvaptanin patients with autosomal dominant polycystic kidney disease.N Engl J Med367(25):2407-2418, 2012. doi: 10.1056/NEJMoa1205511 2.Torres VE, Chapman AB, Devuyst O:Tolvaptanin later-stage autosomal dominant polycystic kidney disease.N Engl J Med16;377(20):1930-1942, 2017. doi: 10.1056/NEJMoa1710030 3.Cadnapaphornchai MA, George DM, McFann K, et al: Effect ofpravastatinon total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.Clin J Am Soc Nephrol9(5):889-896, 2014. 